iRhythm Technologies Announces Second Quarter 2021 Financial Results

Rhea-AI Summary

iRhythm Technologies reported a 59.8% increase in revenue for Q2 2021, reaching $81.3 million compared to $50.9 million in Q2 2020. Despite strong demand for the Zio platform, gross margin declined to 68.0% from 69.6% due to lower Medicare reimbursement rates and increased overtime costs. Operating expenses rose to $72.3 million, causing a net loss of $17.4 million, an improvement from last year's $20.4 million. For 2021, revenue guidance is set at $320-$325 million, reflecting 21%-23% growth.

Positive

• Revenue increased by 59.8% year-over-year to $81.3 million.
• Net loss improved to $17.4 million from $20.4 million a year ago.
• Zio AT surpassed 10% of total revenue for the first time.

Negative

• Gross margin decreased to 68.0% from 69.6% due to falling reimbursement rates.
• Operating expenses rose to $72.3 million, mainly driven by stock-based compensation.

SAN FRANCISCO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended June 30, 2021.

Second Quarter 2021 Financial Highlights

• Revenue was $81.3 million, a 59.8% increase compared to second quarter 2020
• Gross margin was 68.0%, a 1.6% decrease compared to second quarter 2020
• Adjusted EBITDA (defined as EBITDA less stock compensation) was negative $4.6 million
• Cash and Short-Term Investments were $255.7 million as of June 30, 2021, a $6.6 million decrease from March 31, 2021

“Our second quarter results reflected continued strong demand for our Zio platform, as well as solid execution on our operating goals. We were pleased to see growth in both total revenues and unit volumes in the quarter, with Zio AT surpassing 10% of our total revenue for the first time,” said Doug Devine, iRhythm Interim CEO and CFO. “We also made significant advancements to our technology platform in the second quarter with two new 510k clearances that demonstrate our continued commitment to innovation. We are pursuing many opportunities to leverage our technology platform to drive growth and value creation, including through new products such as Zio AT, new indications such as Silent AF, and international expansion. I remain incredibly excited about the future of iRhythm.”

Second Quarter Financial Results
Revenue for the three months ended June 30, 2021 increased 59.8% to $81.3 million, from $50.9 million during the same period in 2020. The increase was primarily driven by a mix of volume growth, improvements in collections performance with some contracted and non-contracted payors, and some favorable pricing adjustments for Zio AT.

Gross profit for the second quarter of 2021 was $55.3 million, up from $35.4 million during the same period in 2020, while gross margins were 68.0%, down from 69.6% during the same period in 2020. The decrease in gross margin was primarily due to a decrease in Zio XT Medicare reimbursement rates, higher overtime costs related to capacity shortfalls offset by volume benefits.

Operating expenses for the second quarter of 2021 were $72.3 million, compared to $55.6 million for the same period in 2020. The increase in operating expenses was primarily due to increases in Stock Based Compensation and payroll offset by decrease in Verily milestone expense.

Net loss for the second quarter of 2021 was $17.4 million, or a loss of $0.59 per share, compared with net loss of $20.4 million, or a loss of $0.75 per share, for the same period in 2020.

Financial Guidance
For the full year 2021, the company expects revenue to range from $320 million to $325 million, representing year over year growth of 21% to 23%. Revenue guidance for the year does not assume any changes to Medicare reimbursement and as disclosed previously discussions with Novitas and the other Medicare Administrative Contractors (MACs) remain ongoing.

Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT/ 4:30 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the “Investors” section of the company’s website at: www.irhythmtech.com.

About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements relating to reimbursement rates and coverage, market expansion, plans to reduce costs and improve efficiency and financial guidance. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filings made with the Securities and Exchange Commission on Forms 10-K and 10-Q. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact
Leigh Salvo
(415) 937-5404
investors@irhythmtech.com

Media Contact
Morgan Mathis
(310) 528-6306
irhythm@highwirepr.com

IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands, except share and per share data)

		June 30,				December 31,
			2021				2020
Assets
Current assets:
Cash and cash equivalents		$	138,872			$	88,628
Short-term investments			116,792				246,589
Accounts receivable, net			63,423				29,932
Inventory			9,261				5,313
Prepaid expenses and other current assets			7,219				7,363
Total current assets			335,567				377,825
Property and equipment, net			47,086				34,247
Operating lease right-of-use assets			87,533				84,714
Goodwill			862				862
Other assets			14,176				14,091
Total assets		$	485,224			$	511,739
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	8,945			$	4,365
Accrued liabilities			42,598				40,532
Deferred revenue			2,507				930
Debt, current portion			11,667				11,667
Operating lease liabilities, current portion			7,301				8,171
Total current liabilities			73,018				65,665
Debt, noncurrent portion			15,515				21,339
Operating lease liabilities, noncurrent portion			87,984				81,293
Other noncurrent liabilities			2,265				1,830
Total liabilities			178,782				170,127
Stockholders’ equity:
Preferred stock			-				-
Common stock			27				27
Additional paid-in capital			656,231				646,258
Accumulated other comprehensive income			7				11
Accumulated deficit			(349,823	)			(304,684	)
Total stockholders’ equity		$	306,442			$	341,612
Total liabilities and stockholders’ equity		$	485,224			$	511,739

IRHYTHM TECHNOLOGIES, INC.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)

	Three Months Ended June 30,							Six Months Ended June 30,
	2021				2020			2021						2020
Revenue, net	$	81,278			$	50,878			$		155,589			$	114,413
Cost of revenue	25,995				15,484					49,453				31,547
Gross profit	55,283				35,394					106,136				82,866
Operating expenses:
Research and development	9,606				12,542				18,116					20,957
Selling, general and administrative	62,669				43,014				132,482					91,244
Total operating expenses	72,275				55,556				150,598					112,201
Loss from operations	(16,992)				(20,162)				(44,462)					(29,335)
Interest expense	(307)				(381)				(642)					(761)
Other income, net	55				237				179					742
Loss before income taxes	(17,244)				(20,306)				(44,925)					(29,354)
Income tax provision	116				131				214					148
Net loss	$	(17,360)			$	(20,437)			$		(45,139)			$	(29,502)
Net loss per common share, basic and diluted	$	(0.59)			$	(0.75)			$		(1.54)			$	(1.09)
Weighted-average shares, basic and diluted	29,318,894				27,176,601					29,242,089				27,008,236

IRHYTHM TECHNOLOGIES, INC.
Reconciliation of Net Loss to Adjusted EBITDA
(Unaudited)
(In thousands)

	Three Months Ended June 30,										Six Months Ended June 30,
	2021					2020					2021					2020
Net loss	$	(17,360	)			$	(20,437	)			$	(45,139	)			$	(29,502	)
Income tax provision	116					131					214					148
Depreciation and Amortization	2,153					1,669					4,189					3,220
Interest expense	247					257					494					60
Stock-based compensation	10,260					9,768					30,490					10,073
Adjusted EBITDA	$	(4,584	)			$	(8,612	)			$	(9,752	)			$	(16,001	)

 

FAQ

What were iRhythm Technologies' Q2 2021 earnings results?

iRhythm reported Q2 2021 revenue of $81.3 million, a 59.8% increase from Q2 2020.

What is the revenue guidance for iRhythm Technologies in 2021?

iRhythm expects full-year 2021 revenue between $320 million and $325 million, indicating 21% to 23% growth.

How did iRhythm's net loss change in Q2 2021?

The net loss for Q2 2021 was $17.4 million, an improvement from a loss of $20.4 million in the same quarter last year.

What were the operating expenses for iRhythm in Q2 2021?

Operating expenses rose to $72.3 million in Q2 2021, up from $55.6 million in Q2 2020.

What factors drove iRhythm's revenue growth in Q2 2021?

Revenue growth was driven by volume growth, improved collections, and favorable pricing for Zio AT.